RxDoctor Payments Data

Jose Lavergne, MD

Gastroenterology · North Miami Beach, FLNPI 1003899212

Payments from drug & device makers

$3,044in general payments, 2019–2025

Across 157 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$790
  • Ferring Pharmaceuticals Inc.$351
  • Bristol Myers Squibb$334
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$231
  • Redhill Biopharma Inc.$199
  • Intercept Pharmaceuticals, Inc.$192
  • plus $947 from 21 others

What the payments were for

  • Food & beverage$3,02499%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,044 in reported general payments places this provider in the 45th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$36,800
Medicare patients
83
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$310,345
LinzessLinaclotide202$212,167
CreonLipase/Protease/Amylase43$184,314
RinvoqUpadacitinib21$171,956
SimponiGolimumab13$93,964
ClenpiqSod Picosulf/Mag Ox/Citric Ac343$58,503
Mesalamine19$15,024
TrulancePlecanatide18$10,966
Esomeprazole Magnesium271$9,582
Colestipol Hcl94$6,287
NexiumEsomeprazole Magnesium11$4,442
Ursodiol18$3,485
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,793
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates44$2,648
Rabeprazole Sodium64$2,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Rinvoq$790$568,437266 claims
Johnson & JohnsonStelara, Simponi$142$404,30925 claims
Ferring Pharmaceuticals Inc.Clenpiq$351$58,503343 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$231$10,96618 claims
AstraZenecaNexium$15$4,44211 claims
Braintree Laboratories, Inc.Sutab$43$2,79317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →